Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALbociclib Collaborative Adjuvant Study
2014-005181-30Phase 3Active
- Sponsor
- Austrian Breast and Colorectal Cancer Study Group
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of palbociclib in breast cancer and estrogen receptor-positive breast cancer (2 arms), sponsored by Austrian Breast and Colorectal Cancer Study Group. Primary endpoint: Invasive disease-free survival (iDFS). Started Jun 2015; status: active.
02
Drugs
palbociclib
03
Conditions
breast cancerestrogen receptor-positive breast cancer
Beyond the preview
Go deeper on 2014-005181-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005181-30.